drug · small molecule
NILOTINIB
Marketedupdated 3mo agoby Xspray Pharma AB🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval14 co-mentions · 7 sources
- tagSmall Molecule6 co-mentions · 6 sources
- drugDANZITEN6 co-mentions · 3 sources
- companyCipla USA Inc4 co-mentions · 2 sources
- drugNILOTINIB HYDROCHLORIDE3 co-mentions · 3 sources
- tagRecall2 co-mentions · 2 sources
- companyHetero Labs Ltd1 co-mentions · 1 sources
- companyCipla Ltd1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and chronic myelogenous leukemia and 24 investigational indications.
targets
Tyrosine-protein kinase ABL1Bcr/Abl fusion protein
all catalysts(1)
Trials studying NILOTINIB
- phase2Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
- phase2Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
- phase4Asciminib Roll-over Study
- phase2Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
- phase3A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
- phase2A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
- phase2Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
- phase2Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
News(1)
- Dr Mauro on the Significance of Alternative TKI Formulations in CMLMichael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.onclive · 3mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that